• Moderna for targeted protein degradation
• Amgen for protein destroying therapies
• CRISPR Therapeutics for small molecule protein degraders

• KT-474 (nemabrutinib): An oral IRAK4 degrader currently in clinical trials for inflammatory and autoimmune diseases.
• KT-621 (KW-103): A STAT3 degrader in clinical development for the treatment of hematological malignancies and solid tumors.
• KT-253: An MDM2 degrader being investigated for advanced liquid and solid tumors in a Phase 1 clinical trial.

Kymera Therapeutics (KYMR) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small molecule protein degraders. As such, it does not sell directly to individuals. Its primary "customers" are other large pharmaceutical companies with whom it forms strategic collaborations, licensing agreements, and partnerships for the development and potential commercialization of its drug candidates.

Based on their business model and public information, Kymera Therapeutics' major customers/partners include:

• Sanofi (SNY)
• Vertex Pharmaceuticals (VRTX)

These collaborations involve upfront payments, research reimbursements, and potential milestone payments and royalties if drug candidates successfully advance through development and commercialization.

Nello Mainolfi, PhD, Founder, President & CEO

Nello Mainolfi is the Co-founder, President, and Chief Executive Officer of Kymera Therapeutics. Prior to co-founding Kymera in 2016, he served as an Entrepreneur in Residence at Atlas Venture. He also led discovery research at the cancer metabolism startup Raze Therapeutics. His career commenced at the Novartis Institutes for Biomedical Research, where he led teams that identified several novel investigational medicines, including the first-in-class, FDA-approved, factor B inhibitor iptacopan. His association with Atlas Venture, a venture capital firm, indicates a connection to private equity backing for early-stage biotech companies.

Bruce Jacobs, CFA, MBA, Chief Financial Officer

Bruce Jacobs serves as the Chief Financial Officer at Kymera Therapeutics, where he is responsible for financial operations, investor relations, and corporate affairs. He joined Kymera with over 25 years of experience in healthcare financial services, investment banking, and equity research. Previously, he was a Managing Partner for Westfield Capital Management, an equity investment firm, and also served on its Management Committee and as the Health Care Team Lead. Mr. Jacobs was also a Director with Alex Brown & Sons/Deutsche Bank, working within their healthcare investment banking group and on the equity research team.

Jeremy Chadwick, PhD, Chief Operating Officer

Jeremy Chadwick is the Chief Operating Officer at Kymera Therapeutics, a position he assumed in May 2023. He brings extensive experience in overseeing global development operations, regulatory, and program management from a variety of biopharmaceutical companies. Before joining Kymera, Dr. Chadwick held the role of Senior Vice President, Head of Global Development Office at Takeda Pharmaceuticals, where he was responsible for Global Regulatory Affairs, Global Drug Safety, and Clinical Supply Chain. Prior to Takeda, he was Group Vice President and Head of Clinical Development Operations at Shire Pharmaceuticals. His earlier career includes senior development roles at The Medicines Company, Synta Pharmaceuticals, Vertex Pharmaceuticals, and Glaxo Group Research. He also previously served as Chairman of the Board of Directors at Accumulus Synergy.

Brian Adams, JD, Chief Legal Officer and Corporate Secretary

Brian Adams is the Chief Legal Officer and Corporate Secretary at Kymera Therapeutics, appointed in September 2025. He previously served as Chief Legal Officer at Relay Therapeutics. His nearly two decades of leadership in the life sciences sector encompass corporate development, strategic planning, and governance. Mr. Adams has also held leadership positions at Keryx Biopharmaceuticals, Algeta ASA, AVEO Oncology, and Genzyme Corporation.

Noah Goodman, MBA, Chief Business Officer

Noah Goodman was appointed Chief Business Officer of Kymera Therapeutics in April 2025. In this role, he is responsible for leading the company's business development strategy and activities. He contributes a diverse wealth of experience from the life sciences industry to Kymera.

Kymera Therapeutics is developing several pipeline products aimed at addressing significant unmet medical needs. The addressable market sizes for its main products are as follows:

• KT-621 (STAT6 degrader): This investigational oral drug targets a range of Th2 diseases, including atopic dermatitis (AD) and asthma. The global addressable market for Th2 diseases encompasses more than 130 million patients worldwide. Specifically for atopic dermatitis, which KT-621 is being developed to treat, the market is estimated to be significant, with one source mentioning a "$6 billion+ market" and another a "$10 billion AD market". The global eczema market, which includes atopic dermatitis, is projected to reach $40.2 billion by 2035.
• KT-474 (IRAK4 degrader): This program is in development for immune-inflammatory diseases such as hidradenitis suppurativa (HS) and atopic dermatitis (AD). While the company has stated this product addresses "significant unmet needs with large market potential," specific numerical market size figures in USD or patient populations are not readily available in the provided information.
• KT-333 (STAT3 degrader): This degrader targets STAT3-dependent hematological malignancies and solid tumors. Specific addressable market sizes in USD or patient populations for the indications KT-333 is targeting were not found in the provided information.

Kymera Therapeutics (KYMR), a clinical-stage biopharmaceutical company, has several expected drivers of future revenue growth over the next 2-3 years, primarily stemming from its robust pipeline and strategic partnerships:

1. Advancement of KT-485 (IRAK4 Degrader) through the Sanofi Partnership: Kymera's collaboration with Sanofi on IRAK4 degraders is a significant potential revenue driver. While Sanofi has decided not to advance KT-474, a new IRAK4 candidate, KT-485/SAR447971, has been selected to proceed to clinical trials, with Phase 1 trials planned for the next year. This partnership has already generated milestone payments and holds the potential for additional development, regulatory, and sales milestones, which could total up to $975 million, along with significant royalty payments upon commercialization.
2. Clinical Development and Potential Commercialization of KT-621 (STAT6 Degrader): KT-621 is a key oral immunology program for Kymera, described as having "dupilumab-like activity." The company completed its Phase 1 healthy volunteer trial, with data expected in June 2025. A Phase 1b trial for moderate to severe atopic dermatitis (AD) has been initiated, with data anticipated in the fourth quarter of 2025. Furthermore, Kymera plans to begin a Phase 2b study for KT-621 in asthma in the first quarter of 2026, indicating a broad potential market for this asset.
3. Introduction and Progression of New Immunology Programs: Kymera is continuously leveraging its targeted protein degradation (TPD) platform to identify and advance new high-value immunology programs. An example is KT-579 (IRF5), a novel oral immunology degrader targeting autoimmune diseases, which is expected to enter Phase 1 clinical trials in early 2026. These new pipeline candidates could unlock additional market opportunities and contribute to future revenue through development, partnerships, or eventual commercialization.
4. Strategic Collaborations and Milestone Payments: Beyond the Sanofi partnership, Kymera's strategy includes forming and maintaining strategic collaborations. These partnerships provide non-product revenue streams through upfront payments and various milestone achievements as their partnered programs advance through clinical development, regulatory approvals, and ultimately, commercialization. Kymera has also reported collaboration revenue from its ongoing partnership with Gilead.

Share Issuance

• In August 2020, Kymera Therapeutics completed an initial public offering (IPO), issuing 8,684,800 common shares at $20.00 per share, which generated approximately $173.7 million in gross proceeds.
• In June 2025, the company announced the pricing of a public offering for approximately $250.8 million, comprising 5,044,500 shares of common stock priced at $44.00 each, along with pre-funded warrants.
• The capital raised from the June 2025 offering is designated to further advance Kymera's pipeline of preclinical and clinical degrader programs focused on immunological diseases.

Inbound Investments

• Kymera received a strategic investment from The Leukemia & Lymphoma Society's Therapy Acceleration Program (TAP) in August 2020 to progress its work on blood-based cancers.
• In June 2025, Kymera entered an exclusive option and license agreement with Gilead Sciences for a novel molecular glue degrader program targeting CDK2, under which Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments.
• As of October 2025, Kymera has active collaborations with partners like Sanofi and Gilead, which have included receipt of milestone payments for pipeline advancements.

Capital Expenditures

• As a clinical-stage biopharmaceutical company, Kymera's capital expenditures are primarily directed towards the development and advancement of its pipeline of preclinical and clinical degrader programs.
• The company reported a significant negative cash flow from operating activities, amounting to an outflow of $79.1 million in the first quarter of 2025, which implicitly includes capital expenditure requirements.
• As of September 30, 2025, Kymera maintained a strong financial position with $978.7 million in cash, cash equivalents, and investments, projected to fund the company into the second half of 2028, thereby supporting ongoing and future capital expenditures for pipeline development.